LoL skins 2025 are finally here, and Riot Games has packed an exciting lineup for all players. These include returning favorites like Cafe Cuties and exciting new themes, like the Masque of the Black ...

Healthcare & Pharmaceuticalscategory Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO January 27, 2025 The German economy is in deep crisis, with gross domestic ...

Use our IPO calendar to view upcoming IPOs and new IPOs. Assess recent IPO prices and public offering value. Keep track of the latest IPO stocks, news and Initial Public Offering (IPO) analysis.

The new season has finally hit the live servers and we have already started seeing major shifts in the meta. With the introduction of Feats of Strength and the new epic monster Atakhan, the game feels ...

Getting new players interested is a necessary part of keeping LoL alive and thriving for years to come. Maddy Marquissee, growth lead for League of Legends, represents that team and is open about ...

If this has you inspired to jump back in, have a look at our LoL tier list and our guide to what League of Legends skins are currently on sale. You can also follow us on Google News for daily PC ...

Other newcomers to the weight-loss drug field include Kailera Therapeutics, which launched in October with $400 million in funding, and Metsera, which debuted in April with $290 million and has ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M initial public offering. While the company didn't specify terms in its SEC filing ...

This $442 million deal significantly boosted Sage's stock value in post-trading. In financial developments, Metsera, a weight-loss drug developer, reported a widened loss in its U.S. IPO filing, ...

If you’re diving into the new season and hoping to ascend through the League of Legends ranks, check out our LoL tier list to ensure you’re locking in the best champs for the job. You can also ...

If J&J fol­lows through with the pos­si­ble deal, it would mark the largest biotech ac­qui­si­tion since 2023. (Bloomberg) Metsera has filed to go public less than a year after its launch. The company ...

Metsera will use its IPO proceeds to fund the Phase III development of its injectable, ultra-long-acting GLP-1 therapy MET-097i, which last week achieved 11.3% weight loss in a Phase IIa study. Just ...